期刊
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
卷 126, 期 1, 页码 45-49出版社
MOSBY-ELSEVIER
DOI: 10.1016/j.jaci.2010.03.042
关键词
Definition; eosinophilia; eosinophilic leukemia; hypereosinophilic syndromes
资金
- GlaxoSmithKline
- AstraZeneca
- Roche
- CSL Behring
- Nycomed
- National Institutes of Health
- Novartis
- Genentech
Because of advances in our understanding of the hypereosinophilic syndrome (HES) and the availability of novel therapeutic agents, the original criteria defining these disorders are becoming increasingly problematic. Here, we discuss shortcomings with the current definition of HES and recent developments in the classification of these disorders. Despite significant progress in our understanding of the pathogenesis of some forms of HES, the current state of knowledge is still insufficient to formulate a new comprehensive etiologic definition of HESs. Nevertheless, we suggest a new working definition that overcomes some of the most obvious limitations with the original definition. (J Allergy Clin Immunol 2010;126:45-9.)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据